Safety of anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection

Journal of Rheumatology

Volumn 35, Issue 10, 2008, Pages 1944-1949

  Ferri, Clodoveo ^a,i   Ferraccioli, Gianfranco ^b   Ferrari, Daniela ^j   Galeazzi, Mauro ^c   Lapadula, Giovanni ^d   Montecucco, Carlomaurizio ^e   Triolo, Giovanni ^f   Valentini, Gabriele ^g   Valesini, Guido ^h  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j NONE

more..

Author keywords

Hepatitis C virus; Rheumatoid arthritis; Safety; Tumor necrosis factor blocker

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; OPPORTUNISTIC INFECTION; ORTHOSTATIC PURPURA; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PURPURA; RATING SCALE; RHEUMATOID ARTHRITIS; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 54949145730     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
2. Desai SB, Furst DE. Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757-90.
3. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
4. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
5. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800-4.
6. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-71.
7. Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology Oxford 2007;46:97-9.
8. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
9. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology Oxford 2006;45:1294-7.
10. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63 Suppl 2:ii18-ii24.
11. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82.
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 2006;18:54-63.
14. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: The GISEA Study. J Rheumatol 2007;34:1670-3.
15. Arase Y, Ikeda K, Chayama K, et al. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000;35:221-5.
16. Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007;Suppl:S59-S67.
17. Buskila D. Hepatitis C associated arthritis. Curr Opin Rheumatol 2000;12:295-9.
18. Fadda P, La Civita L, Zignego AL, Ferri C. Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome. Reumatismo 2002;54:316-23.
19. Rosner I, Rozenbaum M. The case for hepatitis C arthritis. Semin Arthritis Rheum 2004;33:375-87.
20. Sanzone AM, Bégué RE. Hepatitis C and arthritis: an update. Infect Dis Clin North Am 2006;20:877-89, vii.
21. Bombardieri M, Alessandri C, Labbadia G, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004;6:R137-41.
22. Palazzi C, Olivieri I, Cacciatore P, Pennese E, D'Amico E. Management of hepatitis C virus-related arthritis. Exp Opin Pharmacother 2005;6:27-34.
23. Khurana R, Berney SM. Clinical aspects of rheumatoid arthritis. Pathophysiology 2005;12:153-65.
24. Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003;62:482-6.
25. Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology Oxford 2005;44:1414-21.
26. Calabrese LH, Zein N. Biologic agents and liver toxicity: an added concern or therapeutic opportunity? Nat Clin Pract Rheumatol 2007;3:422-3.
27. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.
28. Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006;54:2335-7.